Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston starts EPIC new stent trial

This article was originally published in Clinica

Executive Summary

Boston Scientific has begun a trial of its next-generation EPIC self-expanding nitinol stent system in patients with iliac artery disease. In the disorder, a patient's iliac arteries, which carry blood to the legs, become blocked. The ORION study will enrol 123 patients at 25 US sites, and will measure rates of device- and/or procedure-related major adverse events at nine months. These events are death within 30 days, myocardial infarction occurring during related hospitalisation, target vessel revascularisation, and amputation of the treated limb. The trial will incorporate stent diameter ranges of 6-12mm and lengths up to 120mm. Natick Massachusetts-based Boston launched EPIC in Europe last month, but it is not approved in the US.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT040845

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel